P. Gabriel Steg

Sep 11, 2023 | onlinecjc.ca | S List |P. Gabriel Steg |Université Paris-Cité |Hôpital Bichat

AbstractMany patients require revascularization after index acute coronary syndrome (ACS). Lipoprotein(a) is thought to play a pathogenic role in atherothrombosis. In ODYSSEY OUTCOMES, alirocumab reduced major adverse cardiovascular events after ACS, with greater reduction among those with higher lipoprotein(a) levels. We explored whether risk of revascularization after ACS was modified by the level of lipoprotein(a) and treatment with alirocumab or placebo.